-
Published: June, 2022Source: 2022 EHA Annual Congress Abstract
Early Results of a Safety and Efficacy Study of Allogeneic TruUCAR™ GC502 In Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
EHA 2022 - Poster - Early Results of a Safety and Efficacy Study of Allogeneic TruUCAR™ GC502 In Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
-
Published: June, 2022Source: 2022 EHA Annual Congress Abstract
First-In-Human Study of CD19/BCMA Dual-Targeting FasTCAR-T GC012F For Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
EHA 2022 - Poster –First-In-Human Study of CD19/BCMA Dual-Targeting FasTCAR-T GC012F For Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
-
Published: June, 2022Source: Journal of Clinical Oncology / 2022 ASCO Annual Meeting Abstract
Updated results of a multicenter first-in-human study of BCMA/CD19 dual-targeting FasTCAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM)
-
Published: June, 2022Source: Cancer Research / 2022 AACR Annual Meeting Abstract
Early results of a safety and efficacy study of allogeneic TruUCAR™ GC502 in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
AACR 2022 - Poster – Early results of a safety and efficacy study of allogeneic TruUCAR™ GC502 in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
-
Published: November, 2021Source: Journal for Immuno Therapy of Cancer / 2021 SITC Annual Meeting Abstract
IL-2 Variant Improves CAR-T Functionality and Efficacy Against Solid Tumors
-
Published: November, 2021Source: Blood / 2021 ASH Annual Meeting Abstract
Preclinical Results of an Allogeneic, Universal CD19/CD7-Targeting CAR-T Cell Therapy (GC502) for B Cell Malignancies
ASH 2021 – Poster - Preclinical Results of an Allogeneic, Universal CD19/CD7-Targeting CAR-T Cell Therapy (GC502) for B Cell Malignancies
-
Published: August, 2021Source: Cellular & Molecular Immunology
Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
-
Published: June, 2021Source: 2021 EHA Annual Congress Abstract
Long-term Follow-up Results of a Multicenter First-in-Human Study of the Dual BCMA/CD19 Targeted FasT CAR-T GC012F for Patients with Relapsed/Refractory Multiple Myeloma
Long-term Follow-up Results of a Multicenter First-in-Human Study of the Dual BCMA/CD19 Targeted FasT CAR-T GC012F for Patients with Relapsed/Refractory Multiple Myeloma
-
Published: May, 2021Source: Journal of Clinical Oncology / 2021 ASCO Annual Meeting Abstract
Long-term follow-up results of a multicenter first-in-human study of the dual BCMA/CD19 Targeted FasT CAR-T GC012F for patients with relapsed/refractory multiple myeloma
-
Published: April, 2021Source: 2021 AACR Annual Meeting Abstract
Updates on clinical safety and efficacy result of GC027, the first-in-human, “Off-the-Shelf” CD7 CAR-T stand-alone therapy for adult patients with relapsed/refractory T-cell lymphoblastic leukemia (r/r T-ALL)